Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD51 | Q06609 | 4/20 | 0.51 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | KPNA2 | P52292 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2163077 | 0.93 | RAD51 (0.60) | RAD51TLR9TLR7ALDH1A1SMN1; SMN2 | |
| SCHEMBL2162890 | 0.90 | TLR9 (0.47) | RAD51TLR9TLR7ALDH1A1SMN1; SMN2 | |
| SCHEMBL2164626 | 0.85 | RAD51 (0.48) | RAD51TLR9TLR7ALDH1A1SMN1; SMN2 | |
| SCHEMBL2163616 | 0.82 | RAD51 (0.55) | RAD51ALDH1A1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL2162709 | 0.82 | ADORA2A (0.56) | ALDH1A1SMN1; SMN2MAPTADORA2AKDM4E | |
| SCHEMBL12403830 | 0.81 | MAPT (0.45) | RAD51SMN1; SMN2MAPTADORA2AKDM4E | |
| SCHEMBL2163050 | 0.78 | RAD51 (0.57) | RAD51ADORA2AKDM4ENPC1RAB9A | |
| SCHEMBL2163017 | 0.78 | MEN1 (0.45) | RAD51ALDH1A1SMN1; SMN2MAPTADORA2A | |
| SCHEMBL2162701 | 0.78 | RAD51 (0.64) | RAD51MAPTRAB9A | |
| SCHEMBL2164399 | 0.77 | ALDH1A1 (0.42) | RAD51TLR9TLR7ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2550255-B1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | LILLY CO ELI (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-2550255-B1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | LILLY CO ELI (US) | 2016-04-27 | — | — | EP | disclosed |
| WO-2011119565-A1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-09-29 | — | — | WO | disclosed |
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | MAPT, APP, PSEN1 | RAD51 1902/4885TLR9 4824/4885TLR7 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.